Elanco Animal Health (NASDAQ:ELAN) – Equities researchers at William Blair lowered their FY2019 earnings estimates for shares of Elanco Animal Health in a report issued on Thursday, July 11th. William Blair analyst J. Kreger now anticipates that the company will post earnings per share of $1.07 for the year, down from their previous estimate of $1.08.
ELAN has been the subject of a number of other research reports. UBS Group increased their price objective on Fortis from C$54.00 to C$55.00 in a research note on Wednesday, March 20th. Guggenheim assumed coverage on Elanco Animal Health in a research note on Wednesday, May 22nd. They set a “neutral” rating for the company. Bank of America assumed coverage on DENTSPLY SIRONA in a research note on Monday, March 18th. They set a “buy” rating and a $57.00 price objective for the company. Zacks Investment Research lowered ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, BMO Capital Markets increased their price objective on Sun Life Financial from C$58.00 to C$60.00 in a research note on Friday, May 10th. One analyst has rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company’s stock. Elanco Animal Health currently has a consensus rating of “Hold” and an average target price of $33.56.
NASDAQ:ELAN opened at $33.31 on Friday. Elanco Animal Health has a fifty-two week low of $28.00 and a fifty-two week high of $37.61. The company’s 50 day moving average is $33.00.
Elanco Animal Health (NASDAQ:ELAN) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.03. The company had revenue of $731.10 million for the quarter, compared to analysts’ expectations of $743.40 million. The business’s revenue for the quarter was down .7% compared to the same quarter last year. During the same period last year, the company posted $0.33 EPS.
A number of hedge funds have recently made changes to their positions in the stock. Sterling Investment Advisors Ltd. bought a new position in Elanco Animal Health in the first quarter worth $25,000. Ropes Wealth Advisors LLC bought a new position in Elanco Animal Health in the first quarter worth $25,000. Water Island Capital LLC bought a new position in Elanco Animal Health in the first quarter worth $27,000. FTB Advisors Inc. bought a new position in Elanco Animal Health in the first quarter worth $29,000. Finally, Valeo Financial Advisors LLC raised its holdings in Elanco Animal Health by 376.7% in the second quarter. Valeo Financial Advisors LLC now owns 1,430 shares of the company’s stock worth $48,000 after purchasing an additional 1,130 shares in the last quarter.
In other Elanco Animal Health news, Director John P. Bilbrey purchased 7,750 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The stock was bought at an average price of $32.39 per share, with a total value of $251,022.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
About Elanco Animal Health
There is no company description available for Elanco Animal Health Inc
Read More: How to execute a trade ex-dividend strategy?
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.